JPS611652A - Optical resolution of n-(substituted phenylmethylidene)-phenylalanine methyl ester - Google Patents

Optical resolution of n-(substituted phenylmethylidene)-phenylalanine methyl ester

Info

Publication number
JPS611652A
JPS611652A JP12099184A JP12099184A JPS611652A JP S611652 A JPS611652 A JP S611652A JP 12099184 A JP12099184 A JP 12099184A JP 12099184 A JP12099184 A JP 12099184A JP S611652 A JPS611652 A JP S611652A
Authority
JP
Japan
Prior art keywords
methyl ester
optically active
phenylalanine methyl
phenylalanine
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP12099184A
Other languages
Japanese (ja)
Other versions
JPH0472824B2 (en
Inventor
Yoshio Obara
義夫 小原
Hiroo Matsumoto
浩郎 松本
Kazutaka Arai
和孝 新井
Shuji Tsuchiya
土屋 脩二
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nissan Chemical Corp
Original Assignee
Nissan Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Corp filed Critical Nissan Chemical Corp
Priority to JP12099184A priority Critical patent/JPS611652A/en
Publication of JPS611652A publication Critical patent/JPS611652A/en
Publication of JPH0472824B2 publication Critical patent/JPH0472824B2/ja
Granted legal-status Critical Current

Links

Abstract

PURPOSE:To carry out the crystallization resolution of racemic compound or mixture of phenylalanine methyl ester derivative, without necessitating expensive resolving agent nor enzyme, only with a small amount of seed crystal, by using a base as a racemization agent. CONSTITUTION:The DL isomer of N-(substituted-phenylmethylidene)-phenylalanine methyl ester of formula (X is H, halogen or lower alkoxy) or a mixture of the above compound wherein one of the optical isomer is excess to the other optical isomer, is dissolved in methanol, etc. in the presence of a base (e.g. diazabicycloundecene) as a racemization agent. One of the optically active isomer is seeded to the solution, and the crystallization resolution of the solution is carried out at 80--10 deg.C to obtain the objective compound.

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は式(■)′ (式中、x社水素原子、ハロゲン原子、低級アルコキシ
基を示す。) で表わされるN−(置換フェニルメチリデン)−7ヱニ
ルアラニン メチルエステルの光学活性体の製法に関す
るものである。
Detailed Description of the Invention (Field of Industrial Application) The present invention relates to N-(substituted phenylmethyl The present invention relates to a method for producing an optically active form of methyl ester (Ryden)-7enylalanine.

さらに、前記(1)の化合物の光学活性体は。Furthermore, an optically active form of the compound of (1) above.

またはフェニルアラニンにまで導くことができるので1
本発明は光学活性なフェニルアラニン メチルエステル
またはフェニルアラニンの製法として有用である。
Or it can lead to phenylalanine, so 1
The present invention is useful as a method for producing optically active phenylalanine methyl ester or phenylalanine.

L−フェニルアラニンは必須アミノ酸の一つであり、医
薬品1食品などに用いられる重要なアミノ酸の一つであ
る。また、L−7エ二ルアラニン メチルエステルの光
学活性体も例えば人工甘味料であるアスパルテームの主
原料に用いられるなど有用な物質でおる。
L-phenylalanine is one of the essential amino acids and is one of the important amino acids used in pharmaceutical products, foods, and the like. Furthermore, the optically active form of L-7 enylalanine methyl ester is also a useful substance, such as being used as the main raw material for aspartame, an artificial sweetener.

(従来の技術) 従来、化学的合成により得られるDL体を光学分割する
ことによる光学活性なりエニルアラニンの製法として1
次のようなものが知られている。
(Prior art) Conventionally, as a method for producing optically active enylalanine by optically resolving a DL form obtained by chemical synthesis, 1
The following are known:

(1)N−アシル体の酵素又は微生物による不斉氷解を
利用する方法 (例えば、N−アセチル体にアシラーゼ全作用させる方
法< U、 s、坂5841966  (1949))
、N−アセチル−メチルエステルにアシラーゼを作用さ
せる方法<dy口thesis。
(1) A method that utilizes asymmetric deicing of the N-acyl form by enzymes or microorganisms (for example, a method in which acylase acts entirely on the N-acetyl form < U, S, Saka 5841966 (1949))
, a method for causing acylase to act on N-acetyl-methyl ester.

1983.1041.>。う (2)  光学活性な分割剤を用いるジアステレオマー
法 (例工ば、N−アシル体をキニンで分割する方法< J
、 Am、 Oham、 Soc+−5251(194
9)>。
1983.1041. >. (2) Diastereomer method using an optically active resolving agent (for example, a method of resolving N-acyl forms with quinine <J
, Am, Oham, Soc+-5251 (194
9)>.

エステルをN−アジルアミノ酸で分割スル方法〈特開昭
48−10351tS)、エステルをジペプチド誘導体
で分割する方法〈特開昭55−19234)。) (3)優先晶出による直接分割法 (例工ij、N−アセチル体のアンモニウム塩を用いる
方法く特公昭39’−24440)。
A method for resolving esters with N-azilamino acids (Japanese Patent Application Laid-Open No. 10351/1983), and a method for resolving esters with dipeptide derivatives (Japanese Patent Application Laid-open No. 19234-1983). (3) Direct splitting method by preferential crystallization (Example: Japanese Patent Publication No. 39-24440 for a method using an ammonium salt of N-acetyl compound).

N−アセチル体の7クロヘキシルアンモニウム塩を用い
る方法(特公昭52−8821〉、メチルエステルのモ
ノ硫酸塩を用いる方法〈特開昭48−75540>。)
(解決しようとする問題点) 従来の技術の中で、(1)酵素法及びり2)ジアステレ
オマー法は、高価な酵素または光学活性な分割剤を必要
とし、必ずしも有利な方法とは言えない。一方、(3)
直接分割法は、少量の種晶を用いた晶析操作だけで分割
を行なうことができ、また大量合成にも適するため、工
業的に有利な光学分割法として知られている。
Method using 7-chlorohexylammonium salt of N-acetyl compound (Japanese Patent Publication No. 52-8821>, method using monosulfate of methyl ester <Japanese Patent Publication No. 48-75540>)
(Problems to be solved) Among the conventional techniques, (1) the enzymatic method and 2) the diastereomer method require expensive enzymes or optically active resolving agents, and are not necessarily advantageous methods. do not have. On the other hand, (3)
The direct resolution method is known as an industrially advantageous optical resolution method because it can perform resolution by simply crystallizing using a small amount of seed crystals and is also suitable for large-scale synthesis.

しかしながら、この方法が適用できるのは。However, this method is applicable to:

2セミ体がシセミ混合物を形成するような結晶性の化合
物に限られ、特にフェニルアラニンの誘導体については
、現在のところ、前記(3)の塩類が知られているのみ
である。
This is limited to crystalline compounds in which the 2-semi forms a cis-semic mixture, and in particular, for phenylalanine derivatives, only the above-mentioned salts (3) are known at present.

さらに光学分割においては、不要の対掌体をいかにラセ
ば化して、再利用するかということも経済的に大きな問
題であり、その点でも前記(3)の化合物には、ラセミ
化しにくいという欠点があった。例えば、N−アセチル
体は無水酢酸中で加熱する( Biochem 、 Z
A、205 。
Furthermore, in optical resolution, how to racemize and reuse unnecessary enantiomers is a major economic problem, and in this respect, the compound (3) above also has the disadvantage of being difficult to racemize. was there. For example, the N-acetyl form is heated in acetic anhydride (Biochem, Z
A, 205.

280(1929));エステル体は金属アルコキシド
と反応させる(特開昭54−84522)、ケトン中で
加熱する(特開1@54−109912)などであるが
、厳しい条件のものが多く、また、光学分割の系外に一
旦取シ出して行なう必要があり、操作が煩雑となる欠点
がめった。
280 (1929)); esters are reacted with metal alkoxides (JP-A-54-84522), heated in ketones (JP-A-1@54-109912), etc., but many of them require harsh conditions, and However, it is necessary to take the sample out of the optical separation system, which often results in a complicated operation.

(問題点を解決するための手段) 本発明者は、フェニルアラニンの光学分割に優先晶出法
を適用すべく1種々の誘導体を探索した結果、N−(置
換フェニルメチリデン)−フェニルアラニン メチルエ
ステル(式(I))が、優先晶出可能な化合物であるこ
と全見出した(!¥j願昭59−59156を参照)。
(Means for Solving the Problems) As a result of searching for various derivatives in order to apply the preferential crystallization method to the optical resolution of phenylalanine, the present inventor found that N-(substituted phenylmethylidene)-phenylalanine methyl ester ( It has been found that the formula (I) is a compound which can be preferentially crystallized (see Application No. 59-59156).

さらに、これらの優先晶出可能なN−(置換フェニルメ
チリテン)−フェニルアラニンメチルエステルは、温和
な塩基性条件下で容易にラセミ化することを見出し7’
−、←ト聡墓β そこで、これらの優先晶出とラセば化をうまく組み合わ
せることによシ我、々は極めて効率的なフェニルアラニ
ン誘導体の光学分割法を完成するに至った。
Furthermore, we found that these preferentially crystallizable N-(substituted phenylmethylithene)-phenylalanine methyl esters are easily racemized under mild basic conditions.
−,←Satoshi β Therefore, by skillfully combining these preferential crystallization and racemization, we have completed an extremely efficient optical resolution method for phenylalanine derivatives.

すなわち、N−(置換フェニルメチリデン)−フェニル
アラニン メチルエステルのラセミ体あるいは、一方の
光学活性体が他方の光学活性体よりも過剰に存在する混
合体の優先晶出に際して、ラセミ化剤として塩基を共存
させることによシ、晶析に伴なって母液中に増大する反
対の光学活性体を系内で速カ為にラセミ化させ、晶析分
割の効率を大巾に上昇させる。いわゆるラセミ化優先晶
出法である。
That is, when preferentially crystallizing a racemic N-(substituted phenylmethylidene)-phenylalanine methyl ester or a mixture in which one optically active form is present in excess over the other, a base is used as a racemizing agent. By allowing them to coexist, the opposite optically active substance, which increases in the mother liquor with crystallization, is rapidly racemized within the system, greatly increasing the efficiency of crystallization resolution. This is the so-called racemization preferential crystallization method.

本発明によれば、少量の種晶を用いるだけで、効率よく
光学活性なN−(置換フェニルメチリテン)−フェニル
アラニン メチルエステルを得ることができ、ラセミ化
剤の存在で優先晶出の効率が大巾に上昇していることが
わかる(参考例1と比較)。
According to the present invention, optically active N-(substituted phenylmethylethene)-phenylalanine methyl ester can be obtained efficiently by using only a small amount of seed crystals, and the presence of a racemizing agent improves the efficiency of preferential crystallization. It can be seen that there is a large increase (compared with Reference Example 1).

さらに、得られた光学活性なN−(置換フェニルメチリ
テン)−フェニルアラニン メチルエステルは、温和な
条件で収率良く、光学活性なフェニルアラニン メチル
エステルまたはフェニルアラニンに導くことができる。
Furthermore, the obtained optically active N-(substituted phenylmethylitene)-phenylalanine methyl ester can be converted into optically active phenylalanine methyl ester or phenylalanine in good yield under mild conditions.

(参考例2参照) 本発明の反応条件の詳細について以下に述べる。まず、
N−(置換フェニルメチリデン)−フェニルアラニン 
メチルエステ化のラセミ体あるいは一方の光学活性体が
他方の光学活性体よりも過剰に存在する混合体をラセε
イヒ剤を含んだ有機溶媒に溶解させる。この際、溶液中
では速かにラセば化反応が起ζるので、得ようとする光
学活性体と反対の光学活性体も原料として用いることが
できる。
(See Reference Example 2) Details of the reaction conditions of the present invention will be described below. first,
N-(substituted phenylmethylidene)-phenylalanine
A methyl esterified racemate or a mixture in which one optically active form is present in excess over the other optically active form is
Dissolve in an organic solvent containing a detergent. At this time, since a racemization reaction occurs quickly in the solution, an optically active substance opposite to the optically active substance to be obtained can also be used as a raw material.

使用される溶媒は、ラセミ体の溶解度の方が光学活性体
の溶解度よりも大きいものが好ましい。例えば、ヘキサ
ン、ベンゼン、トルエンのような炭化水素類;エチルエ
ーテル。
The solvent used is preferably one in which the solubility of the racemic form is greater than the solubility of the optically active form. For example, hydrocarbons such as hexane, benzene, toluene; ethyl ether.

イソプロピルエーテルのようなエーテル類;クロロホル
ム、ジクロロメタンのようなハロゲン化炭化水素類;メ
タノール、エタノール。
Ethers such as isopropyl ether; halogenated hydrocarbons such as chloroform, dichloromethane; methanol, ethanol.

イソプロパツール(工pA)、、t−ブタノールのよう
なアルコール類;アセトン、メチルエチルケトン、酢酸
メチ#AD M B O、D M Fのような非プロト
ン性極性溶媒類及びこれらの混合溶媒を用いる仁とがで
きる。
Alcohols such as isopropanol, t-butanol; aprotic polar solvents such as acetone, methyl ethyl ketone, methiacetate, ADMBO, DMF, and mixtures of these solvents. I can do that.

ラセミ化剤としては、アルカリ金属アルコキシド〔例え
ば、ナトリウムまたはカリウム低級アルコキシド(エト
キシド、メトキシド。
Racemizing agents include alkali metal alkoxides such as sodium or potassium lower alkoxides (ethoxides, methoxides).

ブトキシド等)〕あるいはアルカリ土類金属アルコキシ
ド〔例えば、カルシウム低級アルコキシド(メトキシド
、エトキシド、ブトキシド等)〕のような無機塩基、ト
リエチルアミン、ジアザビシクロノナンセン(DBυ″
′)。
butoxide, etc.) or alkaline earth metal alkoxides (e.g., calcium lower alkoxides (methoxide, ethoxide, butoxide, etc.)), triethylamine, diazabicyclononancene (DBυ″
').

ジアザビシクロノナン(DBN)、ジアザビ7り′ロオ
クtン(DBQ)のような含窒塩基等を□用いることが
□できる。
Nitrogen-containing bases such as diazabicyclononane (DBN) and diazabicycloocton (DBQ) can be used.

ラセミ化剤の濃度は、多いほどラセば化反応が速くなる
ので好ましいが、余シ多す虻ると溶液の粘性が高くなっ
たシ、副反応が起こる。塩基の強さによって異なるが9
例えばアルコキシドやDB[J、DBHのような強塩基
の場合’s  ” 1〜20 X (’A ) ll[
カ好”& (、イ。
The higher the concentration of the racemizing agent, the faster the racemization reaction, so it is preferable; however, if it is too high, the viscosity of the solution becomes high and side reactions occur. Although it varies depending on the strength of the base9
For example, in the case of strong bases such as alkoxides, DB[J, DBH's '' 1~20
“Kako” & (, I.

次いで、いずれか一方の光学活性体を接檻して、この種
晶と同一の光学活性体を晶析分割する。種晶の純度は高
め程良<(90X以上が好ましい)、また添加量1粒度
には特に制限はないが1通常は溶液中のラセミ体に対し
、1〜20重量x程度の結晶を砕いた粉末を用いるのが
適当である。
Next, one of the optically active substances is caged, and the same optically active substance as this seed crystal is crystallized and separated. The purity of the seed crystals should be as high as possible (preferably 90X or higher), and there is no particular restriction on the particle size of the seed crystals added, but usually 1 to 20 x crystals by weight are crushed for the racemate in the solution. It is appropriate to use powder.

晶析温度は溶媒の沸点以下であれば可能であり、高温で
ある程ラセミ化反応が速くなるので有利であるが、あま
り高温では溶質量が増えすぎ、溶液の粘性が増すため、
晶析後の結晶の分離が間離になる。一方、あま郵低温パ
では、多量の溶媒を必要とし、光学活性体の収量が低下
する上、ラセミ化反応も遅くなるので不利でちる。通常
80〜−10℃の温度範囲で行なうのが好ましい。
Crystallization is possible if the temperature is below the boiling point of the solvent, and higher temperatures are advantageous because the racemization reaction will be faster, but if the temperature is too high, the amount of solute will increase too much and the viscosity of the solution will increase.
Separation of crystals after crystallization results in spacing. On the other hand, the Amayu low-temperature process is disadvantageous because it requires a large amount of solvent, reduces the yield of the optically active substance, and slows down the racemization reaction. It is usually preferable to carry out the reaction at a temperature in the range of 80 to -10°C.

晶析は、冷却による方法、溶媒を留去する方法、溶解度
が不さい溶媒□を滴下する方法等が可能であり、また回
分法の幌か、連続晶析装置の導入も可能である。この際
、ラセミ化速度と晶出速度の調整が重要である。ラセミ
化速度が晶出速度に比べて遅すぎると種晶と逆の光学活
性体が晶出してしまい、光学線区が低下する。これを避
けるために、ラセミ化速度を上げる九錐には、ラセミ化
剤を増量したり、晶析温度を上げたりし、晶出速度を下
げる壽搬には、冷却速度や過飽和程度を緩和したりする
For crystallization, methods such as cooling, distilling off the solvent, dropping a solvent with poor solubility, etc. are possible, and it is also possible to use a batch method or a continuous crystallizer. At this time, it is important to adjust the racemization rate and crystallization rate. If the racemization rate is too slow compared to the crystallization rate, an optically active substance opposite to that of the seed crystal will crystallize, resulting in a decrease in the optical line width. To avoid this, to increase the racemization rate, increase the amount of racemizing agent or raise the crystallization temperature, and to decrease the crystallization rate, reduce the cooling rate and degree of supersaturation. or

(発明の作用効果) 本発明の光学分割法は、高価な分割剤や酵素を必要とせ
ず、また得られた光学活性体の結晶を次回の種晶として
用いることができるので、最初に少量の種晶を用意する
だけで。
(Effects of the invention) The optical resolution method of the present invention does not require expensive resolving agents or enzymes, and the obtained optically active substance crystals can be used as seed crystals for the next time. Just prepare the seed crystals.

分割が可能となり極めて経済的で一作面でも単なる晶析
操作だけであるため、工業的に有利な方法と言える。
It can be said to be an industrially advantageous method because it allows for division, is extremely economical, and requires only a simple crystallization operation.

さらに9分割工程にラセば化が組み合わせであるので、
ラセミ化工程金別に設ける必要贅 が―御所工程が簡略化される。その上1本来ラセミ体の
中には、一方の光学活性体は。
Furthermore, since the 9-division process is combined with laceration,
The racemization process requires separate preparation for each metal - the palace process is simplified. Furthermore, in the original racemic form, there is one optically active form.

50Xしか存在しないが、クセξ化反応により逆の光学
活性体も分割系内でラセミ化されるため9分割効率が大
巾に上昇し、理論的には原料のすべてを一回の晶析操作
で一方の光学活性体の結晶に変換できる。これは従来法
に比べ画期的な光学分割法であると言える。
Although only 50X exists, the opposite optically active form is also racemized within the separation system due to the customization reaction, so the efficiency of 9 separation increases significantly, and theoretically all of the raw materials can be crystallized in one operation. can be converted into a crystal of one of the optically active substances. This can be said to be an epoch-making optical separation method compared to conventional methods.

なお9本発明で得られた光学活性なN−(置換クエニル
メ−y−IJ テン)−フェニルアラニン メチルエス
テルは収率良く光学活性なフェニルアラニン メチルエ
ステルまたはフェニルアラニンに導くことができる。こ
れは。
Note that the optically active N-(substituted quenylmethane)-phenylalanine methyl ester obtained in the present invention can be converted into optically active phenylalanine methyl ester or phenylalanine in good yield. this is.

本発明が光学活性なりエニルアラニン メチルエステル
およびフェニルアラニンの効率的な製造法として用いる
ことができることを示すものである。
This shows that the present invention can be used as an efficient method for producing optically active enylalanine methyl ester and phenylalanine.

(実施例) 以下に実施例、参考例を示し1本発明をさらに具体的に
説明する。なお、これらの実施例によって本発明が限定
される、ものではない。
(Example) Below, the present invention will be explained in more detail with reference to Examples and Reference Examples. Note that the present invention is not limited to these Examples.

実施例1 N−(p−クロロフェニルメチリゾ/)−フェニルアラ
ニン メチルエステルのDL体485r1kDBUの5
X(騒)メタノール溶液ICLOfに加熱溶解し、30
℃に冷却して1体635ツで’]’;−29K2O(Q
xα5 、0H04):10 (IXa、e、 )を接
種し、5C1でゆっくり冷却した。結晶を戸数し、少量
のメタノールで洗浄後、乾燥すると1945 tの結晶
が得られた(〔α〕$−29t5°:99にe、6.)
Example 1 DL form of N-(p-chlorophenylmethyliso/)-phenylalanine methyl ester 485r1kDBU5
Heat and dissolve in methanol solution ICLOf, 30
-29K2O (Q
xα5,0H04):10 (IXa,e, ) was inoculated and slowly cooled in 5C1. When the crystals were separated, washed with a small amount of methanol, and dried, 1945 t of crystals were obtained ([α] $ - 29 t 5°: 99 e, 6.)
.

これは、L体工918fが得られたことにな)。This means that L bodywork 918f was obtained).

福晶分を除くと原料のDL体の68%にあたる。Excluding the lucky crystal content, it accounts for 68% of the DL form of the raw material.

実施例2 N−(p−クロロフェニルメチリデン)−フェニルアラ
ニン メチルエステルのDL体4、59 fをDBUの
5 X (1)イングロビルアルコール溶液1Q、Of
に加熱溶解し、38℃に冷却して、5体558t9を接
種し、5℃までゆっくり冷却した。結晶を戸数し、少量
ノイングロビルアルコールで洗浄後、乾燥スると187
5fの結晶が得られた−(〔α〕苫−29α1°: 9
9 X e、 e、 )A  これは、L体五8502
が得られたことになり1種晶分を除くと。
Example 2 DL form 4,59 f of N-(p-chlorophenylmethylidene)-phenylalanine methyl ester was added to 5X of DBU (1) Inglovir alcohol solution 1Q, Of
The mixture was heated to dissolve, cooled to 38°C, inoculated with five 558t9, and slowly cooled to 5°C. After washing the crystals with a small amount of Neugrobil alcohol and drying them,
A crystal of 5f was obtained - ([α] Tom -29α1°: 9
9 X e, e, )A This is L body 58502
is obtained, excluding the first seed crystal.

原料のD IJ体の76Xにあたる。Raw material D corresponds to 76X of IJ body.

実施例3 一 旨′(p−クロロフェニルメチリデン)−フェニルアラ
ニン メチルエステルのDrJ体’1.5tをDBUの
2N(□)メタノール溶液&37fに加熱溶解し、25
℃に冷却して5体308グを接種し、5℃までゆっくり
冷却した。
Example 3 1.5t of the DrJ form of ichiji'(p-chlorophenylmethylidene)-phenylalanine methyl ester was heated and dissolved in a 2N (□) methanol solution of DBU & 37f.
The mixture was cooled to 5°C, inoculated with 308 g of 5 plants, and slowly cooled to 5°C.

結晶を濾過し、少量のメタノールで洗浄後。After filtering the crystals and washing with a small amount of methanol.

乾燥すると1.822 fの結晶が得られたー(〔α)
%−21XO°: 73 Xe、e、 )A  これは
、L体1.522 fが得られたことになり9種晶分を
除くと、原料のD IJ体の44Nにあたる。
When dried, a crystal of 1.822 f was obtained ([α)
%-21XO°: 73 Xe, e, )A This means that 1.522 f of the L form was obtained, which corresponds to 44N of the DIJ form of the raw material, excluding the 9 seed crystals.

この結晶をメタノールより再結晶すると。Recrystallize this crystal from methanol.

t 2’8 fの結晶が得られた。(〔α’]’;−2
9140:99Xθ、θ、) 実施例4 J4:″(p−り・・7−=ルメチリデン)−7−二ル
アラニン メチルエステルのDL体&5451をナトリ
ウムメトキシドの20Xメタノ−摩 ル多液CLEFとイソグロビルエーテルalFに加熱溶
解し、25℃に冷却して5体715ツを接種し、5℃ま
でゆっくり冷却した。結晶を戸数し、少量のメタノール
で洗浄後、乾燥すると、18621の結晶が得られた工
(〔α)芸−123,1°: 42X e、 e、 )
A  これはL体1、62 Ofが得られたことになプ
1種晶分を除くと原料のDTJ体の14XIC6たる。
A crystal of t 2'8 f was obtained. ([α']';-2
9140:99 It was heated and dissolved in globyl ether alF, cooled to 25°C, inoculated with 5 715 pieces, and slowly cooled to 5°C.The crystals were separated, washed with a small amount of methanol, and dried to obtain 18621 crystals. ([α) Gei-123, 1°: 42X e, e, )
A: This means that the L-isomer 1,62Of was obtained.If the 1st seed crystal component is excluded, the DTJ-isomer of the raw material is 14XIC6.

実施例5 ル(、−7゜、7.−ヤ2..デy)−フェニルアラニ
ン メ、。チルエステルのDL体804ツと9体5ツの
混合物1DBHの5Xメタノール溶液に加熱溶解し、3
0℃に冷却して。
Example 5 (,-7°, 7.-y2..day)-phenylalanine. A mixture of 804 DL forms and 5 DL forms of thyl ester was heated and dissolved in a 5X methanol solution of 1 DBH, and 3
Cool to 0°C.

L体9oy([α]D−264.4°(0!(L5,0
HO4):9 & 5 X e、e、 )を接種し、5
℃までゆっくり冷却した。
L body 9oy ([α]D-264.4°(0!(L5,0
HO4): inoculated with 9 & 5 X e, e, ), 5
It was slowly cooled to ℃.

結晶をF取し、小量のメタノールで洗浄後乾燥すると、
474sIFの結晶が得られた。
When the crystals are collected by F, washed with a small amount of methanol and dried,
Crystals of 474sIF were obtained.

<Ca]H−2bhq°:100Xe、e、)  これ
は、原料のDL体の425XGCあたる。
<Ca]H-2bhq°: 100Xe, e,) This corresponds to 425XGC of the DL form of the raw material.

(参考例) 参考例1 (ラセば化剤を含まない優先晶出)N−(p
−クロロフェニルメfリゾ7)−フェニルアラニン メ
チルエステルt081tをイソプロビルエーテルーヘキ
テン(1:3(v/v))1覗1tメイソプロピルアル
コール015tの混合溶媒に加熱溶解した。溶液を25
℃に冷却し、D体(〔α]H+2aa6°(C=α5.
0日04 )、 100X e、e、 ) 57ツを接
種し。
(Reference example) Reference example 1 (Preferential crystallization without race forming agent) N-(p
-Chlorophenylmeloflyso7)-Phenylalanine methyl ester t081t was heated and dissolved in a mixed solvent of 1 t of isopropyl ether-hexene (1:3 (v/v)) and 1 t of meisopropyl alcohol 015 t. 25% solution
It was cooled to ℃ and formed into a D-form ([α]H+2aa6°(C=α5.
Day 0: 04), 100X e, e, ) 57 seeds were inoculated.

15分間攪拌した。結晶を戸数し洗浄後、乾燥すると、
209syの結晶が得られたー(ra〕q+qhq°、
 32.5 X e、e、 )4  これは5体681
1pが得られたことになり1種晶分を除くと、11ツ増
えたことになる。
Stirred for 15 minutes. After washing the crystal and drying it,
A crystal of 209sy was obtained (ra]q+qhq°,
32.5 X e, e, )4 This is 5 bodies681
Since 1 p was obtained, excluding the 1 seed crystal, the number increased by 11 p.

参考例2  (L−N−(p−りCi O7x ニルメ
チリデン)フェニルアラニン メチルエステルの加水分
解) N−(p−クロロフェニル4チリデン)フェニルアラニ
ン メチルエステルのb体t51f(99Xe、e、)
をエーテル101Itに溶解し5X塩酸水溶液5fを滴
下した。室温で1時間攪拌後1分液した。エーテル層の
溶媒を留去すると、p−りC1cxベンズアルデヒド(
L6?fが得られ(回収y4 t a X ) *水層
の溶媒を留去し、残渣をメタノールから再結晶するとL
−フェニルアラニン メチルエステル塩酸特許出願人 
日産化学工業株式会社 手続補正書 昭和60年 −月 ノ日 1 事件の表示 昭和59年特許願第120991号 2 発明の名称 +1−(il換フェニルメチリデン)−フェニルアラニ
ン メチルエステルの光学分割法3 補正をする者 事件との関係  特許出願人 住所 101東京都千代田区神田錦町3丁目7番地14
 補正命令の日付 自発補正 6 補正の内容 「発明の詳細な説明−1 1)明細書第9頁第7行の「ノナン」を「ノネン」に補
正する。
Reference Example 2 (Hydrolysis of L-N-(p-Ci O7x nylmethylidene) phenylalanine methyl ester) b-form t51f (99Xe, e,) of N-(p-chlorophenyl 4 tylidene) phenylalanine methyl ester
was dissolved in 101 It of ether, and 5 f of a 5X aqueous hydrochloric acid solution was added dropwise. After stirring at room temperature for 1 hour, the mixture was separated into liquids. When the solvent in the ether layer was distilled off, p-C1cx benzaldehyde (
L6? f is obtained (recovered y4 t a
- Phenylalanine methyl ester hydrochloric acid patent applicant
Nissan Chemical Industries Co., Ltd. Procedural Amendment 1985 - Month Day 1 Indication of the Case 1982 Patent Application No. 120991 2 Title of the Invention + 1 Optical resolution method of -(il-substituted phenylmethylidene)-phenylalanine methyl ester 3 Amendment Relationship with the case of a person who does the following Patent applicant address: 3-7-14 Kanda Nishiki-cho, Chiyoda-ku, Tokyo 101
Date of amendment order Voluntary amendment 6 Contents of amendment “Detailed description of the invention-1 1) “Nonan” on page 9, line 7 of the specification is amended to “nonene”.

4)明細1第15真下から第5行の次に下記文章を挿入
する。
4) Insert the following sentence next to the 5th line from directly below No. 15 of Specification 1.

「実施例6“Example 6

Claims (2)

【特許請求の範囲】[Claims] (1)式( I ) ▲数式、化学式、表等があります▼( I ) (式中、Xは水素原子、ハロゲン原子、低級アルコキシ
基を示す。) で表わされるN−(置換フェニルメチリデン)−フェニ
ルアラニンメチルエステルのDL体、あるいは一方の光
学活性体が他方の光学活性体より過剰に存在する混合体
を、ラセミ化を促進させる塩基の存在下に、溶媒に溶解
させた後、いずれか一方の光学活性体を接種し、晶析分
割することを特徴とする光学活性なN−(置換フェニル
メチリデン)−フェニルアラニンメチルエステルの光学
分割法。
(1) Formula (I) ▲There are mathematical formulas, chemical formulas, tables, etc.▼(I) (In the formula, X represents a hydrogen atom, a halogen atom, or a lower alkoxy group.) N-(substituted phenylmethylidene) - After dissolving the DL form of phenylalanine methyl ester or a mixture in which one optically active form is present in excess of the other optically active form in a solvent in the presence of a base that promotes racemization, either one 1. An optical resolution method for optically active N-(substituted phenylmethylidene)-phenylalanine methyl ester, which comprises inoculating an optically active form of the compound and performing crystallization resolution.
(2)式( I )の式中のXがハロゲン原子である特許
請求の範囲第(1)項記載の光学分割法。
(2) The optical resolution method according to claim (1), wherein X in formula (I) is a halogen atom.
JP12099184A 1984-06-13 1984-06-13 Optical resolution of n-(substituted phenylmethylidene)-phenylalanine methyl ester Granted JPS611652A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP12099184A JPS611652A (en) 1984-06-13 1984-06-13 Optical resolution of n-(substituted phenylmethylidene)-phenylalanine methyl ester

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP12099184A JPS611652A (en) 1984-06-13 1984-06-13 Optical resolution of n-(substituted phenylmethylidene)-phenylalanine methyl ester

Publications (2)

Publication Number Publication Date
JPS611652A true JPS611652A (en) 1986-01-07
JPH0472824B2 JPH0472824B2 (en) 1992-11-19

Family

ID=14800075

Family Applications (1)

Application Number Title Priority Date Filing Date
JP12099184A Granted JPS611652A (en) 1984-06-13 1984-06-13 Optical resolution of n-(substituted phenylmethylidene)-phenylalanine methyl ester

Country Status (1)

Country Link
JP (1) JPS611652A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716062A1 (en) * 1994-12-08 1996-06-12 Ajinomoto Co., Inc. A method of preparing D-amino acid-N-(S)-alpha-alkylbenzylamide
NL1015495C2 (en) * 2000-06-22 2001-12-28 Dsm Nv Method for racemizing an enantiomerically enriched schiff base from an amino acid amide.

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0716062A1 (en) * 1994-12-08 1996-06-12 Ajinomoto Co., Inc. A method of preparing D-amino acid-N-(S)-alpha-alkylbenzylamide
NL1015495C2 (en) * 2000-06-22 2001-12-28 Dsm Nv Method for racemizing an enantiomerically enriched schiff base from an amino acid amide.
EP1167347A1 (en) * 2000-06-22 2002-01-02 Dsm N.V. Process for racemising an enantiomer-enriched schiff base of an amino acid amide
US6846955B2 (en) 2000-06-22 2005-01-25 Dsm N.V. Process for racemising an enantiomer-enriched schiff base of an amino acid amide

Also Published As

Publication number Publication date
JPH0472824B2 (en) 1992-11-19

Similar Documents

Publication Publication Date Title
DK175400B1 (en) Gabapentin, monohydrate
JPS59193845A (en) (+)- and (-)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid:n-methyl-d-glucamine salt mixture
JPS581105B2 (en) Optically active amino acid-mandelic acid complex and method for producing the same
JP3946954B2 (en) Racemate resolution of 2-hydroxypropionic acid
JPH02231457A (en) Method for synthesizing l-(-)-2-amino-3-(3,4- dihydroxyphenyl)propanoic acid, product thereby, and use of said product in said synthesis
JPS61293949A (en) Optical resolution of alpha-isopropyl-p-chlorophenylacetic acid
US6051734A (en) Process for the optical resolution of 3-(p-chlorophenyl)-glutaramide
JPS611652A (en) Optical resolution of n-(substituted phenylmethylidene)-phenylalanine methyl ester
JPS6213942B2 (en)
US3803213A (en) Ephenamine d-(-)-2-acetylamino-2-(4-acetoxyphenyl)acetate
JPS6360955A (en) Manufacture of l-dopa
JP2971291B2 (en) Production method of optically active 2-aminobutyric acid
US3056799A (en) Processes and intermediate products
JPH10506384A (en) Separation of bicyclic lactam enantiomers
JP4135373B2 (en) Method for producing optically active β-phenylalanine derivative
JPH035382B2 (en)
JPH05271169A (en) New optically active t-leucine-1-@(3754/24)4-substituted phenyl) ethanesulfonic acid salt and its production
JPS6363646A (en) Production of optically active homophenylalanine
JPH01221345A (en) Optical resolution of mandelic acid derivative
US3660474A (en) Resolution of ammonium-n-acetyl-dl-alpha-aminophenylacetate and preparation thereof
JPH023628A (en) Production of optically active 1-methyl-3-phenylpropylamine
JPS5830301B2 (en) N-benzoyl-tracis-2-aminocyclohexanecarboxylic acid
JPS58124749A (en) Optical resolution of (+-)-2-amino-1,2-diphenyl ethanol
JPS593476B2 (en) Optically active chlorpheniramine/acylphenylglycine salt and method for producing the same
JPH023627A (en) Production of optically active 1-methyl-3-phenylpropylamine